Article Text

Download PDFPDF
Gynecologic Cancer InterGroup (GCIG) Consensus Review for Ovarian and Primary Peritoneal Low-Grade Serous Carcinomas
  1. Charlie Gourley, MD, PhD, FRCP*,
  2. John Farley, MD,
  3. Diane M. Provencher, MD,
  4. Sandro Pignata, MD, PhD§,
  5. Linda Mileshkin, MD,
  6. Philipp Harter, MD,
  7. Johanna Maenpaa, MD, PhD#,
  8. Jae-Weon Kim, MD, PhD**,
  9. Eric Pujaide-Lauraine, MD, PhD,,
  10. Rosalind M. Glasspool, MBBS, PhD, FRCP,,
  11. Isabelle Ray-Coquard, MD, PhD§§ and
  12. David Gershenson, MD∥∥
  1. *University of Edinburgh Cancer Research UK Centre, MRC IGMM, Edinburgh, United Kingdom;
  2. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Creighton University School of Medicine at St Joseph’s Hospital and Medical Center, Phoenix, AZ;
  3. Centre de recherche du Centre hospitalier de l’Université de Montréal (CRCHUM), Institut du Cancer de Montréal, Montreal, Quebec, Canada, Division of Gynecologic Oncology, Université de Montréal, Montreal, Quebec, Canada;
  4. §Dipartimento di Oncologia Uroginecologica, Istituto Nazionale per lo Studio e la Cura dei Tumori, Fondazione G Pascale, IRCCS, Napoli, Italy;
  5. Division of Cancer Medicine, Peter MacCallum Cancer Centre, St. Andrews Place, East Melbourne, Australia;
  6. Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte, Essen, Germany;
  7. #Department of Obstetrics and Gynecology, Tampere University Hospital, Tampere, Finland;
  8. **Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, South Korea;
  9. ††Université Paris Descartes, Assistance Publique-Hôpitaux de Paris, Paris, France;
  10. ‡‡The Beatson West of Scotland Cancer Centre, Gartnavel Hospital, University of Glasgow, Glasgow, United Kingdom;
  11. §§Département d’Oncologie médicale adulte, Centre Léon Bérard, Lyon, France; and
  12. ∥∥Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
  1. Address correspondence and reprint requests to Charlie Gourley, MD, PhD, FRCP, University of Edinburgh Cancer Research UK Center, MRC Institute of Genetics and Molecular Medicine, Crewe Road South, Edinburgh, UK. E-mail: charlie.gourley{at}ed.ac.uk.

Abstract

Abstract Low-grade serous ovarian cancer is a recently described histological subtype of ovarian cancer that is clinically and molecularly distinct from the 4 other main histological subtypes (high-grade serous, clear cell, endometrioid, and mucinous). In particular, it differs from high-grade serous ovarian cancer in that it presents at a much younger age, is more indolent, and is relatively chemoresistant. Very few clinical trials have been performed exclusively in this tumor type; and as such, specific data guiding optimal management are limited.

  • Low-grade serous
  • Ovarian cancer
  • Primary peritoneal cancer

Statistics from Altmetric.com

Footnotes

  • The authors declare no conflicts of interest.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.